DIRS.INFO The most relevant business & tech news

☆ These are the 7 healthcare startups primed to IPO when the market reopens
▼ + stars: | 2024-01-29 | by ( Rebecca Torrence | ) www.businessinsider.com time to read: +2 min

Only one digital health startup went public in the US in 2022 — digital therapeutics company Akili Interactive, whose shares have since crashed a whopping 97%, per MarketWatch. Not a single healthcare startup went public last year. ArriVent Biopharma went public a few days later, bringing in $175 million. AdvertisementIndustry experts remain skeptical about whether the public markets will be ready for a successful healthcare IPO this year. Business Insider has identified seven startups that could be considering an IPO as the markets reopen, based on conversations with top VCs and bankers and public filings.

Persons: —, Metagenomi, ArriVent Biopharma Organizations: Service, Business, Akili Interactive, Alto Neuroscience, Oncology, BrightSpring Health Services, KKR, Walgreens, Industry

☆ This little-known genome editing stock is poised to surge more than 60%, JPMorgan says
▼ + stars: | 2024-01-29 | by ( Pia Singh | ) www.cnbc.com time to read: +3 min

JPMorgan thinks investors should flock to biotechnology company Beam Therapeutics , which the firm says stands to benefit from increased market share and a strong gene therapy pipeline. "We see BEAM outperforming our coverage over the mid-term, with current levels being an attractive entry point," the analyst said. The stock is down more than 4% so far this year, and has lost more than 42% over the past 12 months. BEAM 1Y mountain Beam stock. He added that BEAM-302 is "uniquely positioned" as a one-time genetic medicine for AATD, particularly given its success in preclinical trials.

Persons: Eric Joseph, Joseph Organizations: Beam Therapeutics, TAM Locations: U.S, 1H24

☆ Stocks making the biggest moves midday: Dollar Tree, iRobot, Bloom Energy and more
▼ + stars: | 2024-01-29 | by ( Hakyung Kim | ) www.cnbc.com time to read: +3 min

Dollar Tree — Shares of the discount retail chain popped 1% following an upgrade to overweight from neutral at JPMorgan. SoFi Technologies — Shares of the financial services provider surged 21% after the company reported its fourth-quarter financial results. ZoomInfo Technologies — Shares jumped more than 6% after Bank of America upgraded shares to buy from neutral on revenue growth acceleration. The firm cited tailwinds including improving market share and volume trends, as well as an attractive valuation and strong top-line growth. Flywire — Shares of the fintech company gained 3.75% after being upgraded by Morgan Stanley to overweight from equal weight.

Persons: McGrath RentCorp, McGrath, SoFi, iRobot, Koji Ikeda, Wells, Flywire, Morgan Stanley, Beam, —, Samantha Subin, Yun Li, Michelle Fox, Alex Harring, Lisa Kailai Han, Sarah Min, Pia Singh, Tanaya Macheel Organizations: WillScot Mobile, JPMorgan, Wall, Amazon, Bain Capital, Western Digital, Kioxia Holdings, Bloom Energy, Bank of America, ZoomInfo, Hershey —, AllianceBernstein, Warner Bros, —, Beam Locations: Japan, AATD

☆ Here are Monday's biggest analyst calls: Nvidia, Netflix, Apple, Micron, Hershey, Dollar Tree, Qualcomm & more
▼ + stars: | 2024-01-29 | by ( Michael Bloom | ) www.cnbc.com time to read: +8 min

JPMorgan upgrades Dollar Tree to overweight from neutral JPMorgan said in its upgrade of the stock that it's a "self-help" story. Bernstein upgrades Hershey to outperform from market perform Bernstein said in its upgrade of the chocolate maker that market share trends are improving. " Goldman Sachs reiterates Nvidia & Micron as buys Goldman said it's standing by shares of Nvidia and Micron. Bank of America upgrades ZoomInfo to buy from neutral Bank of America said the software company is a "self-help" story. Bernstein reiterates Qualcomm as outperform Bernstein said it's bullish heading into Qualcomm earnings later this week.

Persons: Wells, Jefferies, it's, Evercore, Bernstein, Hershey, Goldman Sachs, Goldman, Raymond James, Sherwin, Williams, Morgan Stanley, William Blair, Morgan Stanley downgrades Brown, Forman Organizations: UBS, Amazon, Amazon Web Services, Citi, Air, Deutsche Bank, TFI, Deutsche, JPMorgan, Warner Brothers Discovery, Microsoft, Meta, YouTube, Nvidia, Micron, MU, Netflix, Barclays, Apple, Colgate, Palmolive, " Bank of America, of America, Beam Therapeutics, Bank of America, Builders, Devices, AMD, Qualcomm Locations: Norfolk Southern, Atlanta

☆ Big pharma is at a crossroads, as J&J, Merck and others prepare to lose heaps of revenue from blockbuster drugs
▼ + stars: | 2024-01-28 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +12 min

Bristol Myers Squibb's Eliquis is a blood thinner used to prevent clotting, to reduce the risk of stroke. Bristol Myers Squibb's Opdivo is an immunotherapy used to treat cancers, including melanoma and lung cancer. Investors will get updates on Merck and Bristol Myers Squibb's plans for the years ahead when they report earnings on Thursday and Friday, respectively. That's unlike generics, which are cheaper copycats of small-molecule drugs like Bristol Myers Squibb's Eliquis. Bristol Myers Squibb is also testing a new form of Opdivo, which is currently administered into a patient's veins.

Persons: Johnson, William Blair, Matt Phipps, Bristol Myers, Johnson's, Merck's Keytruda, J's Stelara, Opdivo, Phipps, biosimilars, Eliquis, Biosimilars, Humira, JB Reed, Samsung's, Piper Sandler, Christopher Raymond, AbbVie, Raymond, Chris Schott, Schott, Robert Davis, Keytruda, Davis, JPMorgan's Schott, Bristol Myers Squibb, George Frey, J, Amgen, J confidentially, Mike Perrone, It's, Anna Moneymaker Organizations: New York Stock Exchange, Johnson, NYSE Big, Bristol Myers Squibb, Merck, Biden, William Blair & Company, CNBC, Guggenheim, Bristol, Leerink Partners, Bloomberg, Getty, Bioepis, JPMorgan, JPMorgan Health Care, Moderna, Bristol Myers, Karuna Therapeutics, Hardy, Huntsman Cancer Institute, University of Utah, Reuters, Teva Pharmaceuticals, Pharma, U.S . Department of Health, Human Services Locations: drugmakers, EY, Europe, U.S, Cambridge , Massachusetts, Arda, EY's Americas, Bristol, Salt Lake City , Utah, Washington , DC

Even as the market rallies, the latest short interest data reveals several stocks that could see losses. CNBC Pro screened FactSet data for stocks trading on the New York Stock Exchange and Nasdaq Exchange with the most short interest as of Jan. 12. Lucid Group , another EV maker, saw short interest increase to about 29% of its float. Companies that make auto parts, including Luminar Technologies and Atmus Filtration , also saw short interest increase. Short interest increased 3% and 8% for thrift store chain Savers Value Village and department store Kohl's , respectively.

Persons: Fisker, That's, VinFast, Goldman Sachs, Nick Wells Organizations: Nasdaq, CNBC, New York Stock Exchange, Nasdaq Exchange, Lucid Group, Traders, EV, VinFast, Companies, Luminar Technologies, Dyne Therapeutics, Enliven, Allogene Therapeutics

☆ Cramer's Lightning Round: Buy BlackRock
▼ + stars: | 2024-01-25 | by ( Julie Coleman | ) www.cnbc.com time to read: 1 min

Stock Chart Icon Stock chart icon SolarEdge's year-to-date stock perforamance. Stock Chart Icon Stock chart icon BlackRock's year-to-date stock performance. BlackRock : "I think you buy it. Stock Chart Icon Stock chart icon Axsome Therapeutics' year-to-date stock performance. Stock Chart Icon Stock chart icon HanesBrands' year-to-date stock performance.

Persons: Enphase, they're, Larry Fink, HanesBrands Organizations: BlackRock, Therapeutics, Axsome Therapeutics

☆ Analysts love these biotech stocks, giving 4 more than 100% upside
▼ + stars: | 2024-01-25 | by ( Weizhen Tan | ) www.cnbc.com time to read: +2 min

To look for biotech stocks that did well last year and that analysts are still positive on, CNBC Pro screened the iShares Biotechnology ETF and the SPDR S & P Biotech ETF. Potential upside to average price target of more than 40%. Four stocks stood out for being given on average more than 100% potential upside: Humacyte , Marinus Pharmaceuticals , Olema Pharmaceuticals and Ovid Therapeutics . Another three stocks in the screen drew 100% buy ratings from analysts: Ardelyx , Cabaletta Bio and Rocket Pharmaceuticals . Of these three, Rocket Pharmaceuticals got the highest potential upside of 81.4%.

Persons: Marinus, Biomea Organizations: Citi, Federal Reserve, CNBC Pro, Biotechnology, P Biotech ETF, Marinus Pharmaceuticals, Olema Pharmaceuticals, Ovid Therapeutics, Rocket Pharmaceuticals

☆ Lightning Round: Buy BlackRock 'point blank, period', says Jim Cramer
▼ + stars: | 2024-01-25 | by ( Jim Cramer | ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailLightning Round: Buy BlackRock 'point blank, period', says Jim Cramer'Mad Money' host Jim Cramer weighs in on stock including: Solaredge, Immunome, BlackRock, Hanes and Axsome Therapeutics.

Persons: Jim Cramer Organizations: Hanes, Axsome Therapeutics Locations: Immunome, BlackRock

Gene therapy has allowed several children born with inherited deafness to hear. Globally, 34 million children have deafness or hearing loss, and genes are responsible for up to 60% of cases. Hereditary deafness is the latest condition scientists are targeting with gene therapy, which is already approved to treat illnesses such as sickle cell disease and severe hemophilia. Also, some people consider gene therapy for deafness ethically problematic. "This is real proof showing gene therapy is working,” Chen said.

Persons: ”, Zheng, Yi Chen, Dr, Yilai Shu, Chen, Eli Lilly, Akouos, he's, John Germiller, ” Germiller, “, Lawrence Lustig, Teresa Blankmeyer Burke, ” Chen Organizations: Children's Hospital of Philadelphia, Fudan University, Shanghai Refreshgene Therapeutics, Regeneron Pharmaceuticals, Decibel Therapeutics, Columbia, Gallaudet University, Associated Press Health, Science Department, Howard Hughes Medical Institute’s Science, Educational Media Group, AP Locations: China, Shanghai, Philadelphia, Spain

☆ British billionaire Joe Lewis pleads guilty to U.S. insider trading charges
▼ + stars: | 2024-01-24 | by ( ) www.cnbc.com time to read: +3 min

British billionaire Joe Lewis pleaded guilty to U.S. insider trading charges on Wednesday, and apologized to a judge for his conduct. Lewis, 86, pleaded guilty to one count of conspiracy to commit securities fraud and two counts of securities fraud, as part of an agreement with the U.S. Attorney's office in Manhattan. Addressing U.S. District Judge Jessica Clarke, Lewis said he knew at the time that what he was doing was wrong. Lewis was charged by federal prosecutors with 16 counts of securities fraud and three counts of conspiracy, for alleged crimes spanning from 2013 to 2021. While Lewis will not plead guilty to the other counts under the terms of his deal, Clarke said she may consider them for sentencing purposes.

Persons: Joe Lewis, David Zorno, Valerie Figueredo, Lewis, David Zornow, Jessica Clarke, Patrick O'Connor, Bryan Waugh, Clarke, Damian Williams Organizations: U.S, Tottenham Hotspur, Tavistock Group, Forbes, Aviva, Prosecutors, Mirati Therapeutics, BCTG, Tango Therapeutics, Manhattan U.S Locations: Manhattan, New York City, United States, New York , Florida, Georgia, Mirati

☆ A short-seller who gained over $66,022 in December with a win ratio of 95% shares the 3 red flags that helped him evade short squeezes and led him to have one of his best months
▼ + stars: | 2024-01-21 | by ( Laila Maidan | ) www.businessinsider.com time to read: +7 min

And these short sellers pile up on top of each other with their biased opinions," Capablanca said. But because of the increased number of short sellers, a stock can blow past that and remain elevated over multiple days. So even if the market seems dead, nothing is there to trade, they will force a trade," Capablanca said. This rule helped him avoid Vivos Therapeutics (VVOS), a stock that many short sellers he knew tried to short. Such an outcome could lead to a continued elevated price, driving short sellers out for weeks, he said.

Persons: David Capablanca, lockdowns, Capablanca, it's, POL Organizations: Capablanca, Guardian, Yahoo, Traders, Therapeutics, Yahoo Finance, shorting C4 Therapeutics

☆ Antibiotic-resistant germs are killing us. Microscopic viruses may be the answer
▼ + stars: | 2024-01-21 | by ( Sandee Lamotte | ) edition.cnn.com time to read: +14 min

Last year doctors offered to treat Horton’s infection with one of nature’s oldest predators — tiny tripod-looking viruses called phages designed to find, attack and gobble up bacteria. SCIEPRO/Science Photo Library/Getty ImagesThe microscopic creatures have saved the lives of patients dying from superbug infections and are being used in clinical trials as a potential solution to the growing problem of antibiotic resistance. Would the bacteria from her ear help scientists find phages that would treat the eye infections as well? By the following January, the CDC said at least 50 patients in 11 states had developed superbug infections after using preservative‐free artificial tears. It was a qualified success: The antibiotic-resistant bacteria in five patients were eradicated, while several more patients showed improvements.

Persons: Cynthia Horton’s earaches, “, ”, Dwayne Roach, Eager, Horton, Maroya Walters, ” Walters, Tom Patterson, Steffanie, Paul Turner, “ Iraqibacter, Patterson, Strathdee, Tom, ” Strathdee, Tom Patterson's, Rather, Anthony Maresso, ” Maresso, “ It’s, ” Roach, phages, Elizabeth Villa, Jumbo phages, Robert “ Chip ”, ” Schooley, Juliette Robert, Haytham, REA, CDC’s Walters Organizations: CNN, San Diego State University ., US Centers for Disease Control, Center, Therapeutics, UC San Diego School of Medicine, UC, Diego’s, CDC, Yale University, Yale School of Medicine, UC San, UC San Diego, ”, San Diego, Baylor College of Medicine, Eliava Institute Locations: United States, North America, Pennsylvania, IPATH, Iraq, New Haven , Connecticut, UC San Diego, Turner’s Yale, San, San Diego State, Texas, Houston, Russia, Georgia, Tbilisi , Georgia

☆ What the global elite are saying about AI behind closed doors
▼ + stars: | 2024-01-19 | by ( Matt Turner | ) www.businessinsider.com time to read: +8 min

AdvertisementThe annual World Economic Forum just wrapped up in Davos, Switzerland, and talk of artificial intelligence was just about everywhere. AdvertisementPlenty of companies touted their AI wares at the World Economic Forum in Davos this year. Related storiesAt Automation Anywhere, which, as its name suggests, works on automating work, the customer-service team shrank when AI was implemented. Others I spoke to agreed: Many businesses have small-scale AI experiments running, often with promising results so far. These AI projects are expensive, and not every company has the financial or human capital to pursue an ambitious AI strategy.

Persons: Matt Turner, —, Sam Altman, Rob Goldstein, copilots, Jason Girzadas, he'd, Oliver Wyman, Deb Cupp, Mihir Shukla, Ana Kreacic, Shukla, Becky Frankiewicz, Lareina Yee, WEF, Satish H.C, Mustafa Suleyman, DeepMind, Kapilashram, Azeem Azhar, Dan Vahdat Organizations: Economic, Service, Tech, Infosys, IBM, Builder.ai, Cisco, Qualcomm, Salesforce, BlackRock, Deloitte, Microsoft, Oliver Wyman Group, Standard Chartered, McKinsey, Huma Therapeutics Locations: Davos, Switzerland

☆ Elon Musk is about to find out if ultimatums really work
▼ + stars: | 2024-01-18 | by ( Dan Defrancesco | ) www.businessinsider.com time to read: +7 min

In today's big story, we're looking at the ultimatum Elon Musk gave Tesla's board amid a critical time for the company. The big storyElon's ultimatumREUTERS/Steve NesiusUltimatums rarely work in relationships, but what about between CEOs and the massive companies they run? Elon Musk is about to find out. Musk, who has roughly a 13% stake in the EV maker, said if his request isn't met, he'll "prefer to build products outside of Tesla." Meanwhile, Ross Gerber, a longtime Tesla bull, said it's "absurd" to think Musk doesn't already have control over Tesla and described his request as "blackmailing the Tesla shareholders."

Persons: —, Antony Blinken, Elon Musk, Steve Nesius Ultimatums, Elon, isn't, didn't, Wedbush's Dan Ives, Musk's, Ross Gerber, Tesla, Dow Jones, George Glover, That's, cowering, Caspar Benson, Jamie Dimon, dory, Trump, Ray Dalio, Biden, Evan Spiegel's, Hokyoung Kim, They've, Kristen Stewart, Christopher Nolan, Maite Alberdi, Celine Song, Eugene Lee Yang, Dave Bautista, Kevin Costner, Estelle, AA Milne, Jay Chou, Jennifer Ortakales Dawkins Organizations: Service, Boeing, Business, Tesla, EV, Apple, Microsoft, Nvidia, Getty, Intellia Therapeutics, Shoals Technologies, JPMorgan, Biden, Bridgewater Associates, Trump, Alliance, Helicopter, BI, Sundance, Northern Trust Locations: Switzerland, Tesla, Northern

☆ Why we like health-care stocks in 2024 despite their spotty record in presidential election years
▼ + stars: | 2024-01-18 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +11 min

The S & P 500 Health Care Sector index has outperformed the broader S & P 500 in just three of the past eight presidential election years dating back to 1992, according to FactSet data. So far in 2024, health care has been the best-performing sector in the S & P 500, climbing roughly 2%. .GSPHC .SPX YTD mountain Health care sector vs. S & P 500 YTD It's way too early for any grand predictions with Election Day 2024 about 10 months away. Nevertheless, we see attractive fundamentals in the year ahead for a host of health-care stocks, giving us the confidence to own Lilly, GE Healthcare and Danaher despite what history says about the group in presidential election years. After a strong 2022 for health care in a terrible overall market, investors last year placed a lower emphasis on the defensive characteristics of health care.

Persons: —, that's, Eli Lilly, Lilly, Jim Cramer, Jim, Sen, Bernie Sanders of, Joe Biden, Sanders, would've, Damien Conover, Conover, Biden, Eli Lilly's, Morningstar, Amgen, Morningstar's Conover, Lilly's donanemab, Humana, Bausch, Jim Cramer's, Frederick Florin Organizations: Health, GE Healthcare, Abbott Laboratories, Amgen, Novartis, Walgreens Boots Alliance, JPMorgan Healthcare Conference, Democratic, Morningstar, CNBC, Horizon Therapeutics, Novo Nordisk, Federal Reserve, General Electric, Medicare, Humana, UnitedHealth Group, Investors, AFP, Getty Locations: San Francisco, U.S, Bernie Sanders of Vermont, Canadian, Fegersheim, France

☆ US FDA approves Vertex/CRISPR gene therapy for an inherited blood disorder
▼ + stars: | 2024-01-17 | by ( ) www.cnbc.com time to read: +1 min

The headquarters of US biopharmaceutical company Vertex Pharmaceuticals in Boston, Massachusets, on November 4, 2023. The U.S. health regulator has approved Vertex Pharmaceuticals and CRISPR Therapeutics' gene therapy to treat a rare blood disorder requiring regular blood transfusions, in patients 12 years and older, Vertex said on Tuesday. The decision earns the therapy, branded as Casgevy, the second U.S. approval after it was greenlighted in December for sickle cell disease, another inherited blood disorder. The approval by the Food and Drug Administration comes more than two months ahead of its expected action date of March 30. Oppenheimer analyst Hartaj Singh said he expects a "slow and steady launch" for the therapy and estimated combined peak sales of about $400 million.

Persons: Oppenheimer, Hartaj Singh Organizations: Vertex Pharmaceuticals, Pharmaceuticals, CRISPR Therapeutics, Food and Drug Administration Locations: US, Boston, Massachusets, U.S, United States

☆ Questions and answers for weight loss medications semaglutide and tirzepatide
▼ + stars: | 2024-01-17 | by ( Katia Hetter | ) edition.cnn.com time to read: +10 min

CNN —As prescriptions for popular weight loss drugs have soared, the class of medications known as GLP-1 agonists is changing the way people think about how to lose weight. Initially developed to treat type 2 diabetes, medications like semaglutide and tirzepatide have also been shown to be effective in promoting weight loss. Also, some people would do well without medications and could have sufficient weight loss with changes in diet and exercise. Wen: The FDA-approved versions of semaglutide and tirzepatide for weight loss are called Wegovy and Zepbound. CNN: Are there certain medications that preclude you from taking the weight loss drugs at the same time?

Persons: Leana Wen, Wen, Michael Siluk, tirzepatide, It’s, Eli Lilly Organizations: CNN, US Food and Drug Administration, George Washington University, FDA, BMI, Getty Images CNN, The New England, of Medicine, Novo Nordisk, semaglutide Locations: The

☆ The weight loss drug market may soon get more crowded. Here are the companies trying to enter the booming space
▼ + stars: | 2024-01-17 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

Michael Siluk | UCG | Getty ImagesBoehringer IngelheimBoehringer Ingelheim is developing a weight loss drug with Danish biotech firm Zealand Pharma. Some popular weight loss drugs such as Novo Nordisk's Wegovy only target GLP-1. Terns PharmaceuticalsSmaller drugmakers are developing their own weight loss drugs. Quirk acknowledged that it may be difficult for Terns to set its pill apart from other weight loss drugs. Viking Therapeutics expects to release mid-stage trial data on its weight loss injection in the first half of the year.

Persons: Michael Siluk, Boehringer Ingelheim, Erin Quirk, Quirk, it's, Eli Lilly's, Roger Song Organizations: UCG, Getty, Zealand Pharma, Nordisk's, Drug Administration, JPMorgan Healthcare Conference, Pharmaceuticals, Terns Pharmaceuticals, GLP, Viking Therapeutics, Therapeutics, Jefferies Locations: Viking

☆ 4 stock ideas I brought back from the JPMorgan Healthcare Conference and everything else I learned about the industry
▼ + stars: | 2024-01-15 | by ( Jim Cramer | ) www.cnbc.com time to read: +12 min

We will go over them – but first, let me talk about what I learned at last week's JPMorgan Health Care Conference that I attended in San Francisco, and what it means to your portfolio. We know health care has a lot of angles too it. The previous CEO Roz Brewer was from Starbucks and struggled with the role that Walgreens plays in health care. You have to be following the transformation of Bristol-Myers, which is opening its wallet to buy a host of drug companies, including anti-psychotic firm Karuna. Health care is the way to go.

Persons: Regeneron, Pfizer, Eli Lilly, Dave Ricks, Lilly, donanemab, Lilly's, Zepbound, it's, Abbott, It's, Roche, Merck, Myers, ABT, Robert Ford, Tim Wentworth, He's, Roz Brewer, Wentworth, he'll, Brewer wasn't, Bob Bradway, Amgen, Vas Narasimhan, Sandoz, Karuna, Medtronic, Hugo, Morgan Stanley, Wells, Covid, Cramer's, Jim Cramer, Jim, Las Vegas Brendan Smialowski Organizations: Abbott Labs, Covid, Novartis, Amgen, Walgreens Boots Alliance, JPMorgan Health Care Conference, Humana, Drug Administration, Novo Nordisk, Dickinson Co, Bristol, Myers Squibb, Pfizer, Department, WBA, Walgreens, Starbucks, -, pharma, Merck, Keytruda, Horizon Therapeutics, Federal Trade Commission, Myers, BD, CVS Health, JPMorgan, Cramer's Charitable, CNBC, Consumer, AFP, Getty Locations: San Francisco, GLP, North Carolina, Europe, Cencora, Amgen, West, Bristol, Target, Las Vegas

☆ Investors see a biotech comeback in 2024 as rates fall, deal-making picks up. Stocks to watch
▼ + stars: | 2023-12-28 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +8 min

Many biotech stocks struggled in 2023 despite a robust year for U.S. drug approvals. "We expect this environment to continue but look forward to the prospect of lower interest rates in 2024." When that happens, Canaccord Genuity said to expect a "strong rally across the biotech sector rewarding innovative, but riskier assets." Analysts have said the rich price reflects the opportunity for ImmunoGen's Elahere cancer treatment , which has quickly established itself as the standard of care for types of ovarian cancer. 'Oversold and cheap' In a research note Friday, Jefferies analyst Michael Yee said "a significant short squeeze" was helping biotech stocks in the fourth quarter.

Persons: Dan Lyons, Janus Henderson, John Newman, Canaccord Genuity, Janus, Lyons, Bristol Myers Squibb, Karuna, AstraZeneca, Eli Lilly, AbbVie, Jonathan Miller, Miller, bode, Jonathan Krinsky, Krinsky, BTIG's, Jefferies, Michael Yee, Yee, NASH, Madrigal, we're, David Risinger, — CNBC's Michael Bloom Organizations: Drug, Federal, Bristol Myers, Karuna Therapeutics, CART, Bristol Myers Squibb, Cerevel Therapeutics, Securities and Exchange Commission, pharma, P Biotech, Nasdaq Biotech, Apogee Therapeutics, Madrigal Pharmaceuticals, Madrigal, resmetirom, Vertex Pharmaceuticals, Leerink Partners Locations: ImmunoGen

☆ Oprah's flip on weight loss drugs is a sign of what's to come for the 'Ozempic trade' in 2024
▼ + stars: | 2023-12-25 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +10 min

Lilly's Zepbound recently entered the weight loss market, and is off to a strong start. But what's ahead for the weight loss trade in 2024? Beyond weight loss One of 2023's most pivotal events in the space was Novo Nordisk's release of top line results from its Select trial in August . In 2023, the exuberance around weight loss drugs roiled markets in many unexpected ways. The affected companies have also been very vocal in addressing how they plan to coexist with these weight loss products.

Persons: Oprah Winfrey, Eli Lilly, they've, Lilly's, Lilly's Zepbound, Andy Acker, Janus Henderson's, Lilly, Novo, FactSet, Acker, Janus, Buzz, Gregory Renza, Renza, Goldman Sachs, Chris Shibutani, Mike Kratky, Kratky, Dexcom, Leerink, Winfrey, I've, Winfrey's, Michael Bloom Organizations: Novo Nordisk, Wall Street, Wall, RBC Capital, Pfizer, Structure Therapeutics, AstraZeneca, Leerink, Nestle, Oprah Daily, Winfrey, International Locations: Friday's, Eccogene, MedTech, 3Q23

☆ 25 healthcare startups that are set to take off in 2024, according to top VCs
▼ + stars: | 2023-12-18 | by ( Rebecca Torrence | Blake Dodge | ) www.businessinsider.com time to read: +1 min

AetionAetion's website. AetionPicked by: Lynne Chou O'Keefe, the founder and managing partner of Define VenturesWhat the company does: Aetion provides pharmaceutical companies, payers, and regulators with real-world evidence they can use to inform decisions. Aetion provides the real-world evidence that insurers, pharmaceutical companies, and regulatory agencies need to evaluate the value of drugs and inform those conversations, she said. "The cost of specialty drugs, what's happening in the Inflation Reduction Act — all are bellwethers that we need a more value-based-oriented system around therapeutics going forward," she said. — Shelby Livingston

Persons: Aetion, Lynne Chou O'Keefe, O'Keefe, — Shelby Livingston

☆ Citi says buy this little-known biotech stock with nearly 60% upside
▼ + stars: | 2023-12-05 | by ( Pia Singh | ) www.cnbc.com time to read: +2 min

Battered-down biotechnology stock Travere Therapeutics could see a strong turnaround, according to Citi. Analyst Carly Kenselaar upgraded the clinical-stage company to buy/high risk and raised her price target by $3 to $10, which suggests shares could climb nearly 59% over the next 12 months. Kenselaar's new rating comes after some positive signals indicate the company is on track to obtaining full approval for its Filspari drug. "With the stock trading below cash, we believe risk/reward is skewed quite favorably into a full approval decision, supporting our upgrade," Kenselaar wrote in a Tuesday note. The move would extend its cash runway into 2028, the company said, which Kenselaar pointed to as another catalyst for her increased price target.

Persons: Carly Kenselaar, Kenselaar, Filspari, Travere Organizations: Citi, U.S . Food, FDA Locations: U.S

☆ Here are Tuesday's biggest analyst calls: Netflix, Apple, IBM, Coinbase, Nike, Domino's, Meta, Charles Schwab and more
▼ + stars: | 2023-12-05 | by ( Michael Bloom | ) www.cnbc.com time to read: +9 min

Goldman Sachs reiterates Nike as buy After a transfer of analyst coverage, Goldman Sachs said it sees improving growth for Nike shares. UBS downgrades United Rentals to neutral from buy UBS said in its downgrade of the equipment rental company that it sees a more balanced risk/reward. UBS reiterates Apple as neutral UBS said its analysis of Apple's App Store shows revenue increasing. UBS reiterates Netflix as buy UBS said it's standing by its buy rating on Netflix shares after hosting the company at a conference. William Blair reiterates Charles Schwab as outperform William Blair named Schwab a top pick for 2024, noting it's well-positioned.

Persons: Raymond James, Piper Sandler downgrades Albemarle, Piper Sandler, it's, Goldman Sachs, Roth, Roth MKM, TD Cowen, Bernstein, Mizuho downgrades Prologis, Wells, Wells Fargo, Oppenheimer, Domino's, Elliott, Morgan Stanley, Meta, Needham, Coinbase, JPMorgan, Raymond James downgrades Lululemon, LULU, Strong, William Blair, Charles Schwab, Schwab Organizations: Crescent Energy, Energy Company, Eagle Ford, UW, Nike, Bank of America, UBS, Credit Suisse, Yale, HY, United Rentals, Apple, Semiconductors, JPMorgan, IBM, Consulting, Mizuho, Marriott, of America, Netflix, Management, Integra, Financial, ISI, Disney, BR, Cargo Therapeutics, Citi, Travere Therapeutics Locations: Houston, Uinta, Eagle, LTHM, 2024E, 2025E, Argentina, Boston, China, Mexican

Search resuls for: "THERAPEUTICS"

25 mentions found